Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
however, dedicated cardiovascular outcome trial (CVOT) data have not yet been published, and cardiovascular benefit has not been demonstrated Phase 3 trials are ongoing
That makes supplier transparency, third-party HPLC purity confirmation, and lot-specific certificates non-negotiable for any research-context sourcing
AHK-Cu is a copper-complexed tripeptide (alanine-histidine-lysine bound to copper(II))
High levels of homocysteine are associated with an increased risk of developing cardiovascular disease
US$ 26.18
US$ 25.31
.png)
US$ 22.74
